
It’s a feather in Bavarian Nordic’s cap to have been granted the especially sought-after special regulatory status for the company’s RSV vaccine candidate, dubbed MVA-BN RSV, from the US Food and Drug Administration (FDA) on Monday.
The ”Breakthrough Therapy Designation” is meant to expedite the development and case processing of drugs that treat serious diseases.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app